Table 2.

Main differences between the studies

Study	Percentage with node/adnexal/distant metastases Stage 3b+	death rate at censorship	Control arm	Comparative group	Radiotherapy dose (Gray)	Intervention arm chemotherapy	frequency of cycles
Hogberg	1.6%	23%	hysterectomy and pelvic radiotherapy	No additional treatment	> 44	cisplatin 50mg/m2 + doxorubicin 50 mg/m2 or epirubicin 75 mg/m2 OR paclitaxel 175 mg/m2 + epirubicin 60 mg/m2 or doxorubicin 40 mg/m2 + carboplatin AUC 5 OR paclitaxel 175 mg/m2 + carboplatin AUC 5/6	4 cycles
J GOG 2033	24%	13%	hysterectomy and pelvic radiotherapy	No additional treatment	50	cyclophosphamide(333mg/m2), doxorubicin (40 mg/m2), cisplatin (50mg/m2)	every 4 weeks for 3 or more courses
GICOG	24%	35%	hysterectomy and pelvic radiotherapy	No additional treatment	45 to 50	Cyclophosphamide 600mgm2 doxorubicin 45mgm2 and cis-platin 50mgm2	every 28 days for five cycles
MaNGO	40%	20%	hysterectomy and pelvic radiotherapy	No additional treatment	45	cisplatin 50mg/m2 + doxorubicin 60 mg/m2	every 3 weeks for 3 courses
GOG 34	42%	36%	hysterectomy	50 Gray pelvic radiotherapy	50	doxorubicin (45 mg/m2) up to a cumulative dose of 400	3 weekly
Kuoppala 2008	0	17%	hysterectomy	56gy pelvic radiotherapy divided into two schedules with about 4 weeks break	56	cisplatin 50 mg/m2, epirubicin 60 mg/m2, cyclophosphamide 500mg/m2	there chemotherapy cycles given before, during the break in radiotherapy and after radiotherapy
GOG 122	82%	56%	hysterectomy	30 Gray abdominal radiotherapy plus 50 Gray pelvic radiotherapy	50 +30 to upper abdomen	doxorubicin 60 mg/m2 plus cisplatin 50 mg/m2	every 3 weeks for eight cycles.
GOG 150	Carcinosarcoma study. 56% were stage 3 and 4	41%	hysterectomy	30 Gray abdominal radiotherapy plus 50 Gray pelvic radiotherapy	50 + 30 to upper abdomen	Cisplatin (20 mg/m2/day×4 days) followed by a 1 hour infusion of ifosfamide (1.5g/m2/day IV×4 days) with mesna	every three weeks for three cycles